Access a comprehensive, high-speed research repository designed for instant insights. Evaluate scientific findings with the security and efficiency required by global clinical standards.
Accelerating drug discovery and clinical research through high-performance data architecture and global compliance standards.
Rapidly navigate vast clinical libraries with high-performance search designed for immediate actionable insights.
Unrestricted access to detailed trial protocols, clinical descriptions, and peer-verified scientific outcomes.
Enterprise-grade, unified authentication for clinical centers and global pharmaceutical research organizations.
Discover the most recent research and clinical findings published by our experts.
Four private biotech companies – Charm Therapeutics, CoRegen, Curtana Pharmaceuticals and Iksuda – are putting funds raised from venture financiers to use, moving to start first-in-human studies of pipeline projects. Iksuda already has two clinical-stage assets, but for the first three companies these are the first moves into human trials.
Xencor has become the latest biotech to run into difficulties with hitting Claudin6, admitting on Wednesday to having seen underwhelming efficacy and a toxicity signal with its anti-Claudin6 T-cell engager XmAb541.